Page last updated: 2024-12-05

methoxyacetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Methoxyacetic acid, also known as glycolic acid methyl ether, is a colorless liquid with a pungent odor. It is a versatile chemical used in various industrial and scientific applications. The compound is commonly synthesized through the reaction of methyl chloroacetate with sodium hydroxide. Methoxyacetic acid is known for its antimicrobial and antifungal properties, making it an ingredient in some disinfectants and preservatives. It also serves as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. Research on methoxyacetic acid focuses on its potential applications in fields like agriculture, medicine, and material science. Its biodegradability and relatively low toxicity make it an attractive alternative to some traditional chemicals. Studies are ongoing to explore its use in environmentally friendly herbicides, pesticides, and other industrial applications.'
```

methoxyacetic acid: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

methoxyacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a methoxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID12251
CHEMBL ID1697714
CHEBI ID132098
MeSH IDM0061477

Synonyms (57)

Synonym
unii-f11t1h7q7w
acetic acid, 2-methoxy-
f11t1h7q7w ,
ec 210-894-6
ch3och2cooh
CHEBI:132098
nsc-7300
nsc7300
acetic acid, methoxy-
2-methoxyacetic acid
625-45-6
methoxyacetic acid
methoxyethanoic acid
inchi=1/c3h6o3/c1-6-2-3(4)5/h2h2,1h3,(h,4,5
NCGC00090747-01
nsc 7300
ccris 6518
einecs 210-894-6
brn 0635800
ai3-24152
methoxyacetic acid, 98%
NCGC00090747-02
M0827
AKOS000119404
NCGC00090747-03
CHEMBL1697714
dtxsid1031591 ,
cas-625-45-6
tox21_303516
NCGC00257369-01
dtxcid9011591
NCGC00259120-01
tox21_201571
FT-0628304
alpha-methoxyacetic acid
methoxy-acetic acid
2-methoxy acetic acid
methoxy acetic acid
2-methoxy-acetic acid
(methyloxy)acetic acid
methoxyacetlc acid
J-509848
F2191-0090
mfcd00004308
methoxyacetic acid, analytical reference material
methoxyacetic acid (acd/name 4.0)
2-methoxyaceticacid
CS-W020123
CCG-352130
Q20054532
STR04664
AMY4059
D77874
2-methoxy-d3-acetic acid
HY-Y1009
EN300-20233
Z104477404

Research Excerpts

Overview

Methoxyacetic acid (MAA) is a primary metabolite of the widely used organic solvent and plasticizer, methoxyethanol and dimethoxyethyl phthalate.

ExcerptReferenceRelevance
"Methoxyacetic acid (MAA) is a primary metabolite of the widely used organic solvent and plasticizer, methoxyethanol and dimethoxyethyl phthalate, respectively."( Methoxyacetic acid inhibits histone deacetylase and impairs axial elongation morphogenesis of mouse gastruloids in a retinoic acid signaling-dependent manner.
Li, ASW; Marikawa, Y, 2020
)
2.72
"Methoxyacetic acid (MAA) is a major metabolite of ethylene glycol monomethyl ether (EGME). "( Protein kinase activity is central to rat germ cell apoptosis induced by methoxyacetic acid.
Chapin, RE; Jindo, T; Li, LH; Wine, RN,
)
1.81

Toxicity

ExcerptReferenceRelevance
" When animals were pretreated with inhibitors of alcohol metabolism followed by a testicular toxic dose of EGME (500 mg/kg), an inhibitor of alcohol dehydrogenase (pyrazole) offered complete protection."( Testicular toxicity produced by ethylene glycol monomethyl and monoethyl ethers in the rat.
Creasy, DM; Foster, JR; Foster, PM; Gray, TJ, 1984
)
0.27
" These toxicological properties of methoxyacetic acid are remarkably similar to ethylene glycol monomethyl ether (EGME), and the adverse effects of EGME in rats are probably the result of in vivo bioactivation of EGME to methoxyacetic acid."( Toxicity of methoxyacetic acid in rats.
Carreon, RE; McKenna, MJ; Miller, RR; Young, JT,
)
0.79
" To further examine the toxicity in vitro, luteal cells were recovered from 23-day-old, hCG-primed Sprague-Dawley rats and treated with 0-10 mM methoxy acetic acid (MAA), the proximate toxic metabolite of EGME."( Ovarian luteal cell toxicity of ethylene glycol monomethyl ether and methoxy acetic acid in vivo and in vitro.
Almekinder, JL; Davis, BJ; Flagler, N; Maronpot, RR; Travlos, G; Wilson, R, 1997
)
0.3
" Also, the severity of effects caused by MPA was less than that of MAA, and unlike MAA, MPA was not selectively toxic to the fetus."( Significance of 2-methoxypropionic acid formed from beta-propylene glycol monomethyl ether: integration of pharmacokinetic and developmental toxicity assessments in rabbits.
Breslin, WJ; Carney, EW; Dryzga, MD; Hansen, SC; Johnson, KA; Liberacki, AB; Pottenger, LH; Tornesi, B, 2003
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Based on toxicity information for EGME and related chemicals and accompanied by adverse outcome pathway information on the testicular toxicity of EGME, this category was defined as chemicals that are metabolized to methoxy- or ethoxyacetic acid, a substance responsible for testicular toxicity."( Development of a category approach to predict the testicular toxicity of chemical substances structurally related to ethylene glycol methyl ether.
Hasegawa, R; Hayashi, M; Hirose, A; Ono, A; Sakuratani, Y; Tanaka, Y; Yamada, T; Yamazoe, Y, 2014
)
0.4

Pharmacokinetics

A physiologically based pharmacokinetic (PBPK) model was created to describe the disposition of 2-methoxyethanol (2-ME) and its teratogenic metabolite, 2-MAA, in the pregnant CD-1 mouse.

ExcerptReferenceRelevance
"Using the potent developmental toxicant 2-methoxyethanol (2-ME) as a prototypical compound, a physiologically based pharmacokinetic (PBPK) model was developed to describe the disposition of its primary metabolite and proximate toxicant 2-methoxyacetic acid (2-MAA) in the pregnant CD-1 mouse."( Development of a physiologically based pharmacokinetic model describing 2-methoxyacetic acid disposition in the pregnant mouse.
Conolly, RB; Elswick, BA; Terry, KK; Welsch, F, 1995
)
0.7
"A physiologically based pharmacokinetic (PBPK) model was created to describe the disposition of 2-methoxyethanol (2-ME) and its teratogenic metabolite, 2-methoxyacetic acid (2-MAA), in the pregnant CD-1 mouse."( Pharmacokinetics of 2-methoxyethanol and 2-methoxyacetic acid in the pregnant mouse: a physiologically based mathematical model.
Clarke, DO; Conolly, RB; Elswick, BA; Welsch, F, 1993
)
0.75
" Five related experimental studies were conducted in pregnant C57BL/6CrIBR mice: a conventional dose-response study of developmental toxicity and transplacental pharmacokinetics in mice, a second dose-response study in which reproductive outcomes in litters from individual dams were related to individual pharmacokinetic behavior, a protein-binding experiment, an embryo tissue localization study, and determination of pH in maternal and embryonic compartments after exposure to MAA."( Physiologically based pharmacokinetics of methoxyacetic acid: dose-effect considerations in C57BL/6 mice.
Beliles, RP; McCandless, D; Nau, H; O'Flaherty, EJ; Schreiner, CM; Scott, WJ, 1995
)
0.56
"A physiologically based pharmacokinetic (PBPK) model describing the disposition of 2-methoxyacetic acid (2-MAA; the proximate toxicant derived from oxidation of the ethylene glycol ether, 2-methoxyethanol) was developed in pregnant rodents."( Physiologically based pharmacokinetic models applicable to organogenesis: extrapolation between species and potential use in prenatal toxicity risk assessments.
Blumenthal, GM; Conolly, RB; Welsch, F, 1995
)
0.52
" The objective of the work described here was to adapt an existing physiologically based pharmacokinetic (PBPK) model for 2-ME and 2-MAA kinetics during midorganogenesis in mice to rats on gestation days (GD) 13 and 15."( Development of a physiologically based pharmacokinetic model of 2-methoxyethanol and 2-methoxyacetic acid disposition in pregnant rats.
Blumenthal, GM; Conolly, RB; Elswick, BA; Gargas, ML; Hays, SM; Welsch, F, 2000
)
0.53
" A previously described physiologically based pharmacokinetic (PBPK) model of 2-ME/2-MAA kinetics for rats exposed via oral or iv administration was extended and validated to inhalation exposures."( A toxicokinetic study of inhaled ethylene glycol monomethyl ether (2-ME) and validation of a physiologically based pharmacokinetic model for the pregnant rat and human.
Corley, RA; Gargas, ML; Hays, SM; Mast, TJ; Paustenbach, DJ; Sweeney, LM; Tyler, TR; Weitz, KK, 2000
)
0.31
" Accordingly, a series of in vivo developmental toxicity, whole embryo culture, and in vivo pharmacokinetic experiments were conducted in New Zealand White rabbits (highly sensitive to these compounds) to better understand the developmental toxicity potential of MPA and the kinetics of its formation from beta-PGME."( Significance of 2-methoxypropionic acid formed from beta-propylene glycol monomethyl ether: integration of pharmacokinetic and developmental toxicity assessments in rabbits.
Breslin, WJ; Carney, EW; Dryzga, MD; Hansen, SC; Johnson, KA; Liberacki, AB; Pottenger, LH; Tornesi, B, 2003
)
0.32

Bioavailability

ExcerptReferenceRelevance
" MAA is more rapidly cleared by mice than rats, consequently this study was designed to determine if increasing the bioavailability of MAA in mice might play a role in this species difference."( Repeated high dose oral exposure or continuous subcutaneous infusion of 2-methoxyacetic acid does not suppress humoral immunity in the mouse.
Riddle, MM; Smialowicz, RJ; Williams, WC, 1996
)
0.52

Dosage Studied

ExcerptRelevanceReference
" Rats and mice were dosed by gavage with either ME or MAA in water, at dosages ranging from 50-400 mg/kg/day, for 10 consecutive days."( Differences between rats and mice in the immunosuppressive activity of 2-methoxyethanol and 2-methoxyacetic acid.
Andrews, DL; Copeland, CB; Luebke, RW; Riddle, MM; Smialowicz, RJ; Williams, WC, 1992
)
0.5
" Similarly, there was no good correlation between the combined total 2-ME doses and the fetal malformation rate, although clear dose-response patterns for paw malformations were observed in litters and fetuses for each individual dosing regimen."( 2-Methoxyacetic acid dosimetry-teratogenicity relationships in CD-1 mice exposed to 2-methoxyethanol.
Clarke, DO; Duignan, JM; Welsch, F, 1992
)
1
" Rats were dosed by gavage with MAA on 10 consecutive days at dosages ranging from 50 to 200 mg/kg/day."( Evaluation of the immunotoxicity of orally administered 2-methoxyacetic acid in Fischer 344 rats.
Andrews, DL; Copeland, CB; Luebke, RW; Riddle, MM; Rogers, RR; Smialowicz, RJ, 1991
)
0.53
"3 mmol/kg, single dose concomitant with ME or additional ethanol 5 and 10 hr later) reduced the incidence of malformations 60-100%, depending on the dosing regimen."( The relationship of embryotoxicity to disposition of 2-methoxyethanol in mice.
Greene, JA; Sleet, RB; Welsch, F, 1988
)
0.27
" The present study examined acetate and other simple physiological compounds with close relationships to carbon and one-carbon moiety metabolic pathways for their ability to attenuate digit malformations upon concomitant dosing with ME."( Attenuation of 2-methoxyethanol and methoxyacetic acid-induced digit malformations in mice by simple physiological compounds: implications for the role of further metabolism of methoxyacetic acid in developmental toxicity.
Greene, JA; Sleet, RB; Welsch, F,
)
0.41
" On an equimolar dosage basis, DMEP, 2-ME, and MAA were equally potent, which is consistent with the hypothesis."( Teratogenicity of dimethoxyethyl phthalate and its metabolites methoxyethanol and methoxyacetic acid in the rat.
Randall, JL; Ritter, EJ; Ritter, JM; Scott, WJ, 1985
)
0.49
" Pretreatment of animals with pyrazole (400 mg/kg, ip) 1 hr prior to [14C]ME dosing gave complete protection against the testicular toxicity of ME."( The role of metabolism in 2-methoxyethanol-induced testicular toxicity.
Cook, MW; Creasy, DM; Foster, PM; Gray, TJ; Moss, EJ; Thomas, LV; Walters, DG, 1985
)
0.27
" Embryonic response to MAA varied with gestational age and with dosage (0."( The teratogenicity of methoxyacetic acid in the rat.
Brown, NA; Holt, D; Webb, M, 1984
)
0.58
" Histopathologic changes in the extraembryonic and embryonic tissues induced by an intraperitoneal injection of 250 or 500 mg/kg of 2-methoxyethanol, or its metabolite, 2-methoxyacetic acid, via oral gavage were determined 48 hr after dosing CD-1 mice on day 11 of pregnancy."( Mouse placenta: hemodynamics in the main maternal vessel and histopathologic changes induced by 2-methoxyethanol and 2-methoxyacetic acid following maternal dosing.
Khera, KS, 1993
)
0.69
" Five related experimental studies were conducted in pregnant C57BL/6CrIBR mice: a conventional dose-response study of developmental toxicity and transplacental pharmacokinetics in mice, a second dose-response study in which reproductive outcomes in litters from individual dams were related to individual pharmacokinetic behavior, a protein-binding experiment, an embryo tissue localization study, and determination of pH in maternal and embryonic compartments after exposure to MAA."( Physiologically based pharmacokinetics of methoxyacetic acid: dose-effect considerations in C57BL/6 mice.
Beliles, RP; McCandless, D; Nau, H; O'Flaherty, EJ; Schreiner, CM; Scott, WJ, 1995
)
0.56
" Rats and mice were dosed orally twice a day for 4 days by gavage with MAA at dosages ranging from 40-320 mg/kg/day and 240-1920 mg/kg/day, respectively."( Repeated high dose oral exposure or continuous subcutaneous infusion of 2-methoxyacetic acid does not suppress humoral immunity in the mouse.
Riddle, MM; Smialowicz, RJ; Williams, WC, 1996
)
0.52
" Dose-response and time-course studies (four to nine rats per group per treatment) determined that 300 mg/kg EGME suppressed cyclicity without systemic toxicity within 3 to 8 days, and doses less than 100 mg/kg had no effect."( Ovarian luteal cell toxicity of ethylene glycol monomethyl ether and methoxy acetic acid in vivo and in vitro.
Almekinder, JL; Davis, BJ; Flagler, N; Maronpot, RR; Travlos, G; Wilson, R, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
mutagenAn agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
etherAn organooxygen compound with formula ROR, where R is not hydrogen.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency61.13060.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency1.25330.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency28.18380.000221.22318,912.5098AID588515
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency59.39740.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency36.73080.001530.607315,848.9004AID1224841; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency0.03160.005428.02631,258.9301AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency24.88690.000229.305416,493.5996AID743069; AID743080
activating transcription factor 6Homo sapiens (human)Potency54.94100.143427.612159.8106AID1159516
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (137)

TimeframeStudies, This Drug (%)All Drugs %
pre-199026 (18.98)18.7374
1990's50 (36.50)18.2507
2000's36 (26.28)29.6817
2010's22 (16.06)24.3611
2020's3 (2.19)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.37 (24.57)
Research Supply Index5.02 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index60.90 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (1.32%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other149 (98.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]